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Abstract
OBJECTIVE: To evaluate the medium- to long-term
efficacy of ligustrazine plus conventional medicine
treating ischemic stroke.
METHODS: Randomized controlled trials (RCTs)
testing ligustrazine in the treatment of acute isch-
emic stroke were retrieved from Cochrane Library,
PubMed, Excerpta Medica Database, Chinese Medi-
cal Journal Database, Chinese Biomedical Data-
base, China National Knowledge Infrastructure Da-
tabase, and Chinese Clinical Trial Register, and then
identified by the inclusive and exclusive criteria.
The quality of trials was assessed with the Co-
chrane Handbook 5.1, a risk of bias assessment
tool. RevMan 5.1 was used for meta-analysis.
RESULTS: Three RCTs involving 643 patients were
included. Compared to conventional medicine
treatment alone, ligustrazine plus conventional
medicine treatment showed significant difference
in reduction of stroke recurrence either at the end
of 1-year follow-up [RR=0.42, 95% CI (0.18, 0.94), P<
0.05] or 3-years observation [RR=0.48, 95% CI (0.27,
0.83), P<0.05]. The ligustrazine group also showed
higher survival rate [RR=1.67, 95% CI (1.02, 0.2.71),
P<0.05] and significantly better effective rate [RR=
1.28, 95% CI (1.10, 1.50), P<0.05] than that of the
control group at the end of 1 year visit. Only one tri-
al conducted safety assessment and no adverse
events were reported. The methodological quality
of all the trials included was generally poor.
CONCLUSION: The findings provided evidence
that the combination of ligustrazine and conven-
tional medication was medium- and long-term ben-
eficial to the patients suffering ischemic stroke. But
more RCTs of high quality are needed to further
prove the efficacy and safety of using ligustrazine
for ischemic stroke.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Ischemia, the most common type of stroke,1 is the ma-
jor cause of death, disability and long-period hospital-
ization in China.2 The economic burden will be contin-
uously rising in the coming 20 years for treating it in
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developing countries due to aging population and
changes of life style.3 Except anti-platelet therapy, Chi-
nese patent medicine (CPM) has been used for the pre-
vention and treatment of ischemic stroke in China.4
However, the efficacy of the CPM was controversial in
clinical studies. Therefore, application of evi-
dence-based methodology to evaluate these trials is im-
portant for confirmation of CPM efficacy.
Ligustrazine (Tetramethylpyrazine, short form as
TMP),5 a bioactive ingredient extracted from a wide-
ly-used Chinese herb, Chuanxiong (Rhizoma Chuanx-
iong), was proved to have beneficial effect on cerebro-
vascular diseases in pharmacological experiments. It tar-
gets at platelet-aggregation inhibition,6 vessel-dilation
enhancement,7 cerebral blood flow increase8 and neuro-
logical protection.9 CPM made of TMP has been clini-
cally used in patients with ischemic stroke for over 10
years.10
Our previous evidence-based study indicated that
TMP injection used in acute phase of ischemic stroke
was safe and beneficial in hemodynamics while showed
no better improvement in current neurological defi-
cit.11 In order to provide more evidence for the combi-
nation of TMP and conventional medication in the
treatment of ischemic stroke, we analyzed randomized
controlled trials (RCTs) of ischemic stroke treated with
TMP plus conventional medication, which carried out
follow-up for more than 3 months.
MATERIALS ANDMETHODS
Eligibility
Eligible studies were defined as RCTs with either
known methodology or not. Patients meeting the diag-
nosis criteria of ischemic stroke with confirmation of
computed tomography (CT) or magnetic resonance
imaging (MRI) scanning of any sex and age were in-
cluded. The primary outcomes included death or sur-
vival and recurrence while the secondary measurement
was clinical efficacy. It was calculated according to the
improvement neurological deficit and daily life. All out-
comes were measured at least at the end of 3-month
follow-up.
Search strategy and study selection
Studies including all language were electronically
searched in PubMed (1966-2012), the Cochrane Li-
brary (issue 12, 2012), Excerpta Medica Database (EM-
base) (1980-2012), Chinese Clinical Trial Register
(ChiCRT, 2005-2012), Chinese Biomedical Database
(CBM, 1979-2012), China National Knowledge Infra-
structure Database (CNKI, 1979-2012), and Chinese
Medical Journal Database (CMJD, 1989).
We identified and selected the studies through the fol-
lowing procedure. Initially RCTs testing TMP were in-
cluded and then abstracts were screened to exclude
non-ischemic stroke studies and duplicate publica-
tions. Then the full text of remaining articles were care-
fully read and studies mismatching the diagnostic and
outcome eligibility were eliminated. All articles were
maintained and classified in MedRef database (version
3.0, King Yee, Beijing, China).
Data management
The extracted data were entered into the Excel library,
covering publication information, methodological de-
sign, participants, intervention, control, death, surviv-
al, recurrence and efficacy.
Methodological assessment
The methodological assessment was conducted using
risk of bias assessment tool according to the principle
of Cochrane Handbook for Systemic Reviews of Inter-
ventions 5.1.12 Six aspects were evaluated, including
randomization sequence generation, allocation conceal-
ment, blinding, incomplete outcome data, selective re-
porting and other bias source.
The study identification, data extraction and method-
ological assessment were conducted by two reviewers
separately. Once the dispute occurred, a third person
would be invited for verification.
Statistical analysis
Review Manager (RevMan) (version 5.1.Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collabo-
ration, 2011) was used to conduct the Meta-analysis.
Because the outcomes were all presented in dichoto-
mous data, they were reported by relative risk (RR)
with 95% confidence interval (CI). Heterogeneity be-
tween trials was tested by Chi-square test. For the
study with good homogeneity (P>0.1, I2<40%), fixed
model was used for Meta-analysis. If there was het-
erogeneity, subgroups analysis was conducted or the
random model was used with results carefully ex-
plained. Funnel plot analysis was carried out to de-
tect the publication bias if more than 10 RCTs were
finally included.
RESULTS
Search results
A total of 3 RCTs13-15 were finally included into the re-
view. All studies were published in Chinese. The flow
diagram of search and identification results is shown in
Figure 1.
Study characteristics
A total of 643 patients aged 31 to 82 years old13-15 were
included into the review. All trials applied modern diag-
nostic criteria16,17 of ischemic stroke and CT or MRI
scanning for confirmation. All experiment groups re-
ceived conventional medicine treatment (anti-platelet
therapy included) as well as TMP injection, daily dos-
ages of which varied from 80-240 mg. Each study had
different treatment timing after stroke onset; one start-
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ed within 14 days,13 one within 100 days14 and the rest
within 6 months.15 The total duration of TMP therapy
were also different; one trial had a 10-days continuous
treatment at 2-months interval for 3 years,15 one had a
1-week interval treatment for 1 months13 and the re-
maining one had a constant treatment for 1 year.14 Two
trials conducted 1-year follow-up13,14 while another one
visited the participants for 3 years.15 One trial assessed
the 1-year and 3-years recurrence as well as 3-years sur-
vival;15 one14 reported the effectiveness based on the
neurological deficit improvement and daily life ability
grading recommend at the Chinese National Cerebro-
vascular Diseased Conference in 1995;18 the rest
showed the 1-year recurrence of ischemic stroke.13
None of the trials reported the mortality or fatality.
Only one of the studies conducted safety evaluation
and no adverse events were found.13 Details are shown
in Table 1.
Methodological quality and risks of bias
The methodological quality of all the trials included
was generally poor. No trial described the method of
randomization and allocation concealment. None of
the trials used blinding. All trials simply reported the
baseline information and only one conducted the com-
parability analysis.15 No drop-out or lost to follow-up
were mentioned and none applied intention-to-treat
analysis. The risks of bias were shown in Figure 2.
Recurrence
The recurrence at the end of 1 year follow-up was re-
ported in 2 trials.13,15 The recurrence events in control
groups were significantly higher than that of experi-
mental groups [RR=0.42, 95% CI (0.18, 0.94), P<
0.05] (Figure 3). The recurrence at the end of 3 years
follow-up was reported in only 1 trial.15 The recurrence
events in control groups were significantly higher than
that of experimental groups [RR=0.48, 95% CI (0.27,
0.83), P<0.05] (Figure 4).
Death or survival
Death was not reported in any trials included. One tri-
al reported the survival at the end of 3 year follow-up.15
The survival rate in experimental groups were also sig-
nificantly higher than that of the control groups [RR=
1.67, 95%CI (1.02, 2.71), P<0.05] (Figure 5).
Efficacy
The efficacy at the end of 1 year follow-up was ana-
lyzed and compared in only 1 trial.14 The experimental
group showed significantly better effective rate than
that in control group [RR=1.28, 95% CI (1.10, 1.50),
P<0.05] (Figure 6).
DISCUSSION
The time course of recovery from ischemic stroke
should be considered when selecting the timing of as-
sessment. Spontaneous recovery of neurological func-
tion does not plateau until 3 to 6 months after stroke,
especially the severe ones.19 Six months, at lease 3
months after stroke might be the appropriate time to
measure the efficacy.20 So it's better to measure
long-term outcomes in order to evaluate the definite ef-
fect of the intervention. Considering the pathophysiol-
ogy of stroke impairment and healing, we included the
trials which assessed the outcomes in at least 3 months
in this review and found TPM plus conventional medi-
cine was a beneficial therapy. This result showed that
additional use of TMP for a longer period strength-
Notes: E: experimental group; C: control group; TMP: ligustrazine; CMT: conventional medicine treatment. The studies are labeled as
the first author with the publishing year.
Study
Zhang
XJ
200515
Liu
HL
200214
Yang
L
200013
Number
(E/C)
42/30
258/261
32/20
Gender (E/C)
Male
27/22
134/139
28
Female
8/15
124/122
24
Age (years)
(E/C)
45-82 Mean 67/
49-84 Mean 71
40-79 Mean 61/
39-80 Mean 62
31-81 Mean59/
40-80 Mean 60
Intervention
(E/C)
TMP plus
CMT/CMT
TMP plus
CMT/CMT
TMP plus
CMT/CMT
Follow
-up
(years)
3
1
1
Outcome
Death/
Survival
Known
Unknown
Unknown
Recurrence
Known
Unknown
Known
Effectiveness
Unknown
Known
Unknown
Table 1 Summary of studies included in the review
2128 potential papers for abstract screening
1964 papers were eliminated for
non-ischemic stroke studies or dupli-
cate publications
164 articles for full text evaluations
161 papers were excluded for mis-
matching with diagnostic and out-
come eligibility
3 RCT finally included
Figure 1 The flow diagram of study search and identification
RCT: randomized controlled trials
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ened survivability, reduced recurrence, and improved
efficacy in terms of neurological function and daily life
ability.
The severity of acute ischemic stroke is determined by
the reduction of cerebral blood flow (CBF) and the re-
perfusion timing.21 Once the artery is occluded, CBF is
sharply decreasing and the neuron dies in very short
time, mostly in a few hours and several days.22 Penum-
Figure 3 Comparision of 1-year recurrence rate between ligustrazine + CMT and CMT
CMT: conventional medicine treatment.
Figure 4 Comparision of 3-year recurrence rate between ligustrazine + CMT and CMT
CMT: conventional medicine treatment.
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Figure 2 risks of bias summary for the included studies
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bra was marginal area between the ischemic center and
normal brain tissue, normally recovering in 4.5 h,
which was called time window.23 Thrombolysis is the
only recommend therapy to reducing neurological defi-
cit and disability in the time window.24 However, it
hasn't been widely used in developing countries, be-
cause timely treatment seldom occurs with lack of com-
prehensive post-thrombolysis monitoring and rescue
professionals.25 Therefore, the prevention of stroke re-
currence is important in China, especially in remote
and undeveloped areas. In our study, the combined use
of TMP and conventional medication was proved to re-
duce the recurrence of ischemic stroke either at the end
of 1 or 3 years follow-up compared to conventional
therapy alone, which provides clinical evidence for
medical professionals.
The goal for ischemic stroke management is to reduce
the death and disability, which should be used as the
main outcome to evaluate any intervention.26 However,
it was found that very few RCTs applied primary end-
point (death or dependency) to assess the effect of
TMP for ischemic stroke in this study and only 1 trial
reported the survival rate at the end of 1-year follow
up. Besides, the poor quality of the eligible literatures
was another problem. First, blinding was not intro-
duced in all trials included, the baseline was varied and
few studies conducted safety evaluation. Second, all tri-
als were not reported in accordance with the CON-
SORT statement.27 Third, registration was not conduct-
ed to present full transparency for the performance and
reporting of the trials.28
CONCLUSION
The findings in the study show that TMP combined
with conventional treatment was beneficial to the pa-
tients with ischemic stroke in a medium- and
long-term way. Yet more RCTs with better methodolo-
gy and rigorous practice are needed to further corrobo-
rate the findings.
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